Company: AZN
Filing Date: 2025-06-26
Form Type: 11-K
Source: 0001683168-25-004771
Chunk: 3

Company: ASTRAZENECA PLC
Filing Date: 2025-06-26
Form: 11-K
Chunk 3
---
                                              |     |      | 1,747,604,509 |
| Deductions                                                   |     |      |               |
| Benefits paid to participants                                |     |      |   703,642,913 |
| Administrative expenses                                      |     |      |       521,746 |
| Total deductions                                             |     |      |   704,164,659 |
| Net increase                                                 |     |      | 1,043,439,850 |
| Net assets available for benefits:                           |     |      |               |
| Beginning of the year                                        |     |      | 7,610,111,717 |
| End of the year                                              |     | $    | 8,653,551,567 |

<div align='center'>The accompanying notes are an integral part of these financial statements.</div>

| 5 |

<div align='center'>ASTRAZENECA SAVINGS AND SECURITY PLAN

Notes to Financial Statements

December 31, 2024 and 2023

_______________</div>

| 1. | Description of Plan: |

General:

The
following description of the AstraZeneca Savings and Security Plan (the “Plan”) provides only general information. Paiticipants
should refer to the Plan document for a more complete description of the Plan’s provisions. The Plan, formerly known as the Zeneca
Deferred Compensation Plan, was established on April l, 1958, and was designed to provide a systematic means of saving and investing
for the future.

Effective
July I, 2000, the Zeneca Deferred Compensation Plan was amended and restated as the Plan sponsorship transferred from Zeneca Inc. to
AstraZeneca Pharmaceuticals LP (the “Company”). Regular full-time and part-time employees of the Company are immediately
eligible to participate in the Plan. The Company is an indirect wholly owned subsidiary of AstraZeneca PLC. The Plan is subject to the
provisions of the Employee Retirement Income Security Act of 1974 (“ERISA”).

The
Plan is intended as a plan described in Section 404(c) of ER!SA and Section 2550.404c-l of Title 29 of the Code of Federal Regulations.
Because the Plan allowed participants to invest both before-tax and after-tax contributions in AstraZeneca PLC American Depositary Receipts
(“ADRs”), the Plan and the stock offered thereunder are registered under the Securities Act of 1933 (the “Act”).
Participants have not been